What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
STAT2d
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
BioPharma Dive1d
Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
FierceBiotech2d
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Stocktwits on MSN1d
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong
Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...
Arrowhead climbs after licensing deal with Sarepta
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing ...
Sarepta price target lowered to $202 from $205 at Needham
Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with clear long-term ...
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets ...
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Commerce Bank
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Business Insider2d
Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy ...